Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.